Did anyone else read the Washington Post article about estimated drug valuations that I posted earlier today, or did the trolls succeed in hijacking the board?

If you read the article, you will see that estimated sales of the 10 drugs they expect to be approved are mostly above a billion, and most are not aimed at the very large population that IPIX's drugs would help.

Here's the link again:
https://www.washingtonpost.com/news/powerpost...ab13b777e7

And here's another excerpt from the article. Please note that the goal is non-progresion for a year for 56% of patients.

Quote:

---

3. Epacadostat; Incyte: $1.6 billion

This drug could be the year’s most-anticipated cancer immunotherapy. Designed as a first-line treatment for metastatic melanoma, it’s used in combination with Merck’s Keytruda. Studies have shown that 56 percent of melanoma patients treated with the combination responded to the therapy for a median 45 weeks , and their cancer didn’t progress for a median 12.4 months. The FDA probably won’t approve the drug until late in the year, given the hurdles still facing Incyte.

---